| SGLT2抑制剂联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的研究进展 |
| |
| 引用本文： | 赵喆,杨丹丹,詹晓蓉. SGLT2抑制剂联合GLP-1受体激动剂治疗2型糖尿病合并心血管疾病的研究进展[J]. 临床与病理杂志, 2019, 0(6): 1337-1341 |
| |
| 作者姓名： | 赵喆 杨丹丹 詹晓蓉 |
| |
| 作者单位： | 哈尔滨医科大学附属第一医院内分泌三科 |
| |
| 摘 要： | 目前糖尿病患病率越来越高,且相当大一部分合并心血管疾病,SGLT2抑制药及GLP-1受体激动药可从降糖、减重、降压、保护肾功等多个角度间接及直接地减少糖尿病患者的心血管不良事件和心血管病病死率。
|
| 关 键 词： | 2型糖尿病 心血管事件 钠葡萄糖协同转运蛋白2抑制剂 胰高血糖素样肽-1受体激动剂 |
Research advance in SGLT2 inhibitor combined with GLP-1 receptor agonist in the treatment of type 2 diabetes with cardiovascular disease |
| |
| ZHAO Zhe,YANG Dandan,ZHAN Xiaorong. Research advance in SGLT2 inhibitor combined with GLP-1 receptor agonist in the treatment of type 2 diabetes with cardiovascular disease[J]. Journal of Southern Agriculture, 2019, 0(6): 1337-1341 |
| |
| Authors: | ZHAO Zhe YANG Dandan ZHAN Xiaorong |
| |
| Affiliation: | (Third Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China) |
| |
| Abstract: | ZHAO Zhe;YANG Dandan;ZHAN Xiaorong(Third Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China) |
| |
| Keywords: | type 2 diabetes mellitus cardiovascular events sodium glucose cotransporter 2 inhibitors glucagon like peptide 1 receptor agonists |
| 本文献已被 CNKI 维普 等数据库收录！ |
